Log In
Print
BCIQ
Print
Print this Print this
 

Quillivant XR, methylphenidate

  Manage Alerts
Collapse Summary General Information
Company Tris Pharma Inc.
DescriptionOnce-daily, extended-release liquid methylphenidate developed using OralXRplus technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat attention deficit hyperactivity disorder (ADHD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today